Last reviewed · How we verify
ASP1707 single dose fasted — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
ASP1707 single dose fasted (ASP1707 single dose fasted) — Astellas Pharma Europe B.V..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| ASP1707 single dose fasted TARGET | ASP1707 single dose fasted | Astellas Pharma Europe B.V. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- ASP1707 single dose fasted CI watch — RSS
- ASP1707 single dose fasted CI watch — Atom
- ASP1707 single dose fasted CI watch — JSON
- ASP1707 single dose fasted alone — RSS
Cite this brief
Drug Landscape (2026). ASP1707 single dose fasted — Competitive Intelligence Brief. https://druglandscape.com/ci/asp1707-single-dose-fasted. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing